<DOC>
	<DOCNO>NCT01983839</DOCNO>
	<brief_summary>At Department Infectious Diseases , Aarhus Denmark , moxifloxacin use empirical treatment severe community-acquired pneumonia ( CAP ) . This study design determine pharmacokinetics moxifloxacin 400 mg/day patient treat empirically CAP . To accomplish aim , establish pharmacokinetic population model . This approach adopt dual purpose assess potential efficacy drug perform Monte-Carlo simulation characterize maximal MICs recommend pharmacokinetic-pharmacodynamic ( PK-PD ) target obtain pathogen commonly know cause CAP .</brief_summary>
	<brief_title>PK Analysis Moxifloxacin Treatment CAP</brief_title>
	<detailed_description>We determine pharmacokinetic profile moxifloxacin 400 mg/day 18 patient treat empirically community-acquired pneumonia . . Moxifloxacin plasma concentration determine day therapy initiation use ultra high performance liquid chromatography . The moxifloxacin plasma concentration-time profile describe one compartment model , use NONMEM . Peak drug concentration ( Cmax ) 24-hour area free drug concentration-time curve value ( fAUC0-24 ) predict patient evaluated epidemiological cut-off MIC value Streptococcus pneumoniae , Haemophilus influenzae Legionella pneumophilia . PK-PD target adopt Cmax/MIC â‰¥ 12.2 pathogen , fAUC0-24/MIC &gt; 34 S. pneumoniae fAUC0-24/MIC &gt; 75 H. influenzae L. pneumophilia . The PK-PD estimate use simulation probability target attainment ( PTA ) versus MIC .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients communityacquired pneumonia , treat moxifloxacin Under 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Moxifloxacin</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>